AR088619A1 - Metodo para preparar complejos de polipeptidos fisiologicamente activos - Google Patents

Metodo para preparar complejos de polipeptidos fisiologicamente activos

Info

Publication number
AR088619A1
AR088619A1 ARP120104102A ARP120104102A AR088619A1 AR 088619 A1 AR088619 A1 AR 088619A1 AR P120104102 A ARP120104102 A AR P120104102A AR P120104102 A ARP120104102 A AR P120104102A AR 088619 A1 AR088619 A1 AR 088619A1
Authority
AR
Argentina
Prior art keywords
physiologically active
active polypeptide
conjugate
peptide polymer
polypeptide
Prior art date
Application number
ARP120104102A
Other languages
English (en)
Inventor
Su Kim Seung
Soo Lee Jong
Hyun Jang Myung
Jin Kim Dae
Hyuk Choi Jae
Chang Kwon Se
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of AR088619A1 publication Critical patent/AR088619A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método para preparar un conjugado de un polipéptido fisiológicamente activo seleccionado del grupo de la insulina y un polímero no peptídico por unión del polipéptido fisiológicamente activo a dicho polímero no peptídico mediante un enlace covalente usando un solvente orgánico, y para preparar un complejo de un polipéptido fisiológicamente activo por unión del conjugado con un vehículo para mejorar la duración y la estabilidad in vivo de dicho polipéptido fisiológicamente activo. El método permite preparar el conjugado del polipéptido fisiológicamente activo y el polímero no peptídico con una gran pureza y rendimiento. Los complejos de polipéptidos fisiológicamente activos preparados con esta característica permiten reducir el costo de producción y extender la actividad in vivo a un nivel relativamente alto, y además aumentar significativamente la vida media en sangre. Por consiguiente, se puede emplear eficazmente en el desarrollo de una formulación de liberación sostenida de un polipéptido fisiológicamente activo que permite elevar la adaptabilidad del paciente para tomar la droga.
ARP120104102A 2011-11-04 2012-11-01 Metodo para preparar complejos de polipeptidos fisiologicamente activos AR088619A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110114828A KR20130049671A (ko) 2011-11-04 2011-11-04 생리활성 폴리펩타이드 결합체 제조 방법

Publications (1)

Publication Number Publication Date
AR088619A1 true AR088619A1 (es) 2014-06-25

Family

ID=48192386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104102A AR088619A1 (es) 2011-11-04 2012-11-01 Metodo para preparar complejos de polipeptidos fisiologicamente activos

Country Status (17)

Country Link
US (1) US11434271B2 (es)
EP (1) EP2773672B1 (es)
JP (2) JP6336394B2 (es)
KR (1) KR20130049671A (es)
CN (2) CN103930447A (es)
AR (1) AR088619A1 (es)
AU (1) AU2012331750B2 (es)
BR (1) BR112014010818A2 (es)
CA (1) CA2854078A1 (es)
ES (1) ES2898718T3 (es)
IL (1) IL232387B (es)
MX (1) MX369480B (es)
RU (1) RU2624129C2 (es)
SG (1) SG11201401677VA (es)
TW (1) TWI617569B (es)
WO (1) WO2013066106A1 (es)
ZA (1) ZA201403189B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
CN117065044A (zh) * 2014-03-31 2023-11-17 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
TW201718022A (zh) * 2015-07-24 2017-06-01 韓美藥品股份有限公司 製備生理活性多肽接合物的方法
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
US20200283492A1 (en) * 2017-09-29 2020-09-10 Hanmi Pharm Co., Ltd. Long acting protein complex having an enhanced efficiency
CN113166271A (zh) * 2018-05-18 2021-07-23 郑州晟斯生物科技有限公司 具有延长半衰期的融合多肽缀合物
CN110964116A (zh) * 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
CN109384840A (zh) * 2018-10-23 2019-02-26 福州大学 蛋白质的修饰与分离纯化以及巯基蛋白酶的酶活调控方法
CN112521481B (zh) * 2020-12-08 2022-11-04 武汉市工程科学技术研究院 表面修饰物及其制备方法和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110906A (en) 1986-08-21 1992-05-05 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
JP2004510751A (ja) * 2000-10-05 2004-04-08 アレス　トレーディング　ソシエテ　アノニム 位置選択的液相ペグ化
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
DK2599502T3 (en) * 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
PL1824988T3 (pl) * 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
CA2589647A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
EP1920061A4 (en) 2005-07-27 2009-05-13 Wang Qinghua GLP / 1 / EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR THE TREATMENT OF DIABETES
UA97628C2 (ru) 2005-08-16 2012-03-12 Ханми Холдингз Ко., Лтд. Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе
KR100824505B1 (ko) 2005-08-16 2008-04-22 한미약품 주식회사 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5577243B2 (ja) 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2184355A4 (en) 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd WITH A HYDROPHOBIC MOLECULE MODIFIED ANTIBODY
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
MY151184A (en) 2008-07-23 2014-04-30 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
CA2755395C (en) * 2009-03-20 2015-02-24 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
JP5657698B2 (ja) 2010-01-19 2015-01-21 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型顆粒球コロニー刺激因子結合体の液剤
US8829163B2 (en) 2010-01-19 2014-09-09 Hanmi Science Co., Ltd Liquid formulations for long-acting erythropoietin conjugate
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) * 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR101830344B1 (ko) 2010-10-26 2018-02-22 한미사이언스 주식회사 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN103502264A (zh) 2011-04-04 2014-01-08 国立大学法人东京医科齿科大学 Hiv立体结构识别抗体诱导肽
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
EP2721062B1 (en) 2011-06-17 2018-11-14 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
BR112014005091A2 (pt) 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
RU2620072C2 (ru) 2011-10-06 2017-05-22 Ханми Сайенс Ко., Лтд. ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
AU2013216943B2 (en) 2012-02-10 2018-04-19 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
EP2875152B1 (en) 2012-07-19 2019-10-09 Oxford Nanopore Technologies Limited Enzyme construct
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
ES2748158T3 (es) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
CA2899418C (en) 2013-02-26 2022-05-03 Hanmi Pharm. Co., Ltd. Site-specific insulin conjugate
TWI755579B (zh) 2013-02-26 2022-02-21 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
KR102136336B1 (ko) 2013-03-05 2020-07-22 한미약품 주식회사 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CA2925416A1 (en) 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
EA038544B1 (ru) 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip
IL263934B2 (en) 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd A derivative of glucagon, its conjugate, a preparation containing it and its medical use

Also Published As

Publication number Publication date
US11434271B2 (en) 2022-09-06
TWI617569B (zh) 2018-03-11
CA2854078A1 (en) 2013-05-10
AU2012331750A1 (en) 2014-05-22
CN108210934A (zh) 2018-06-29
JP2014532695A (ja) 2014-12-08
RU2014117563A (ru) 2015-12-10
WO2013066106A1 (en) 2013-05-10
IL232387B (en) 2019-11-28
BR112014010818A2 (pt) 2017-06-13
US20140296475A1 (en) 2014-10-02
KR20130049671A (ko) 2013-05-14
CN103930447A (zh) 2014-07-16
NZ624338A (en) 2016-11-25
AU2012331750B2 (en) 2017-06-15
EP2773672A4 (en) 2015-03-18
SG11201401677VA (en) 2014-05-29
RU2624129C2 (ru) 2017-06-30
ZA201403189B (en) 2015-08-26
JP6336394B2 (ja) 2018-06-06
ES2898718T3 (es) 2022-03-08
MX369480B (es) 2019-11-08
IL232387A0 (en) 2014-06-30
EP2773672B1 (en) 2021-09-15
TW201323435A (zh) 2013-06-16
JP2018150332A (ja) 2018-09-27
EP2773672A1 (en) 2014-09-10
MX2014005353A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
AR088619A1 (es) Metodo para preparar complejos de polipeptidos fisiologicamente activos
AR075913A1 (es) Metodo para preparar un conjugado polipeptidico fisiologicamente activo de sitio especifico
ECSP10010677A (es) Compuestos de insulina lispro pegilada
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
DOP2017000239A (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
PE20120583A1 (es) Sistemas basados en conjugados para entrega farmacologica controlada
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
MX341427B (es) Un conjugado de insulina que usa un fragmento de inmunoglobulina.
EA201692282A1 (ru) Композиция для лечения сахарного диабета, содержащая инсулин и двойной агонист glp-1/глюкагона
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2012145752A3 (en) Wearable automatic injection device
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
MX2018006844A (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
EP4360621A3 (en) Formulations of bendamustine
UY33490A (es) Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos.
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
ECSP13013095A (es) Composición farmacéutica que comprende fexofenadina
WO2013018055A3 (en) Protection and accommodation system for devices for delivering treatment to a patient
BR112013031040A2 (pt) multímero insulina-polímero não peptidil e método para a produção dos mesmos
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
WO2010083154A3 (en) Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles
MX2018001041A (es) Concentrado que contiene alprostadil.
RU2011153314A (ru) Способ введения лекарственных средств в полость коленного сустава у собак

Legal Events

Date Code Title Description
FB Suspension of granting procedure